<DOC>
	<DOCNO>NCT00605995</DOCNO>
	<brief_summary>The overall purpose study determine whether cholesterol-lowering drug simvastatin effective treatment symptom schizophrenia . The primary hypothesis patient schizophrenia receive add-on treatment simvastatin improve clinically ( measure mainly symptom severity ) compare patient receive placebo , improvement accompany concomitant reduction peripheral inflammatory marker .</brief_summary>
	<brief_title>Add-on Simvastatin Schizophrenia Trial</brief_title>
	<detailed_description>The identification alternative therapy capacity dampen inflammatory process reduce serum cholesterol take additional significance give independent concern heighten cardiovascular risk schizophrenia patient , exposure antipsychotic drug , increase cholesterol level , metabolic syndrome obesity , smoking .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Age 1870 year Available follow study protocol DSMIV schizophrenia Positive Negative Syndrome Scale ( PANSS ) baseline score ≥50 Score 3 high Severity Illness scale Clinical Global Impression ( CGI ) Not completely refractory antipsychotic : evidence least partial responsiveness antipsychotic medication Evidence current clinical stability Capacity provide inform consent Provided inform consent Patients take concomitant , noninvestigational medication list Exclusion Criteria # 1 Patients speak Spanish English Women use acceptable method birth control , include barrier method Currently take statin OR following : Other lipidlowering drug ; Antiinflammatory drug aspirin ; Systemic antibiotic , antiviral antifungal drug ( within past 4 week ) ; Potent inhibitor cytochrome P450 isoform 3A4 ( CYP3A4 ) ; Digoxin ( Lanoxin® ) , nefazodone ( Serzone® ) , niacin , cyclosporine ( Neoral® , Sandimmune® ) , danazol , warfarin ( Coumadin® ) , amiodarone , verapamil , Cordarone® , Inderal® . Patients know hypersensitivity simvastatin statin drug Active liver disease unexplained persistent elevation serum transaminase Renal insufficiency Serious unstable medical condition require close medical attention , cancer , unstable heart failure , uncontrolled hypertension/asthma/COPD Current drug use disorder ( abuse/dependence ) Pregnancy lactation Psychiatric disorder schizophrenia schizoaffective disorder require pharmacotherapy Suicidal homicidal intent Severe cognitive impairment might compromise competency sign inform consent validity cognitive outcome measure Organic brain disorder , include epilepsy ; mental retardation ; medical condition whose pathology treatment would likely alter presentation treatment schizophrenia Current participation another clinical trial Patients 2 antipsychotic medication ( patient taper effective medication purpose participate research ) LDL cholesterol &gt; 100 mg/dL know coronary hard disease . LDL cholesterol &gt; 130 mg/dl 2 follow risk factor : smoking ; hypertension ; low HDL cholesterol ( &lt; 40 mg/dL ) ; age &gt; 45 year ( men ) age &gt; 55 year ( woman ) ; family history premature CHD ( CHD 1st degree relative male &lt; 55 ; female &lt; 65</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Randomized trial</keyword>
	<keyword>Statin</keyword>
	<keyword>Placebo</keyword>
</DOC>